Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound

Moussa, Hesham G.; Martins, Ana M.; Husseini, Ghaleb A.

doi:10.2174/1568009615666150311100610

Cited by 47 publications

(42 citation statements)

References 227 publications

(375 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Zununi Vahed et al 2017) The extracellular pH level in the environment of cancer cells is lower than that around normal cells (pH 6.2-6.8 vs pH 7.1-7.4). Additionally, in endosomal vesicles, the pH is lower than 5 (Moussa et al 2015). pH-sensitive liposomes (PSLs) are stable at the neutral pH of blood and healthy tissues, but are designed to become destabilized and release encapsulated drugs in the vicinity of cancer cells and/or in endosomes (Karanth & Murthy 2007).…”

Section: Liposomesmentioning

confidence: 99%

Combination Strategies for Targeted Delivery of Nanoparticles for Cancer Therapy

He¹,

Liu²,

Byrne³

et al. 2019

Applications of Targeted Nano Drugs and Delivery Systems

View full text Add to dashboard Cite

Pharmaceuticals, and more recently biopharmaceuticals, have become the mainstay for antineoplastic treatments in combination with surgical interventions and radiation therapy. In recent years, advances have been made in the development of nanotechnological interventions for the treatment of cancer alone or in combination with existing therapeutic modalities. Nanotechnology used for therapeutic drug delivery and sensitization of photodynamic, sonodynamic and radiotherapy are now being tested in preclinical and clinical trials for the treatment of cancer. This article will review the current state of the art for nanotechnology therapies with an emphasis on targeted drug delivery and the observed and likely benefits when used in combination with existing therapeutic approaches.

show abstract

Section: Liposomesmentioning

confidence: 99%

Combination Strategies for Targeted Delivery of Nanoparticles for Cancer Therapy

He¹,

Liu²,

Byrne³

et al. 2019

Applications of Targeted Nano Drugs and Delivery Systems

View full text Add to dashboard Cite

show abstract

“…Triggering in drug delivery is defined as the method that allows the control of drug release in its amount, its location and the period in which it is being released [6]. Several triggering techniques, such as pH, temperature, enzymes and light stimuli, have been suggested to release liposome-encapsulated drugs [7][8][9][10].…”

Section: Triggering Stimulusmentioning

confidence: 99%

“…Researchers have conducted extensive studies on micellar [37,40,42,43,[60][61][62][63][64][65][66] and liposomal [6,11,36,38,39,47,65] UStriggered release and enhanced cellular uptake. Studies using ES-conjugated liposomes and US, however, are scarce.…”

Section: Lfus-induced Releasementioning

confidence: 99%

“…Trigger-stimulated drug release. The release of the drug from the nanocarriers at the tumor site was enhanced by either applying external stimulus, such as ultrasonic or magnetic waves, or internal mechanism within the structure of the nanocarriers that responds to tumor-specific environment, such as pH, temperature, enzymes or light stimuli [6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy

Salkho

Paul

Kawak

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

A new modality of drug targeting to tumors has been proposed. The ligand-mediated approach, that already increases the therapeutic index of the drug, can still be optimized by the encapsulation of the drug into sonosensitive nanoparticles. In this work, an endogenous ligand, estrone, was used to synthesize doxorubicin-encapsulating liposomes for estrogen receptor (ER)-positive breast cancer therapy with cyanuric chloride (2,4,6 trichloro-1,3,5 triazine) being used as a linking molecule to attach 3-OH group of estrone to the surface of liposomes. Then, drug release from liposomes was studied using ultrasound waves as a triggering mechanism with different frequencies and power densities. In addition, drug uptake by two cell lines ER-positive (MCF-7) and ER-negative (MDA-MB-231) was assessed, with the former cell line being examined later to study the synergetic effect of the receptor mediator targeting and ultrasound trigger. The sizes of the liposomes loaded with calcein (as a doxorubicin model drug) were determined by dynamic light scattering, and they were characterized as large unilamellar vesicles (LUVs). The release from the prepared liposomes triggered by ultrasound (US) waves at low frequency (20 kHz) and high frequency (1.07 and 3.24 MHz), at several power densities, was determined by monitoring the changes in calcein fluorescence, using a spectrofluorometer. Increasing power densities showed a significant effect on release at high frequencies and during the first two US pulses at low frequency. The echogenicity of the liposomes was proven and characterized at different power densities and frequencies. To confirm the viability of the carrier as a doxorubicin carrier, doxorubicin-encapsulating liposomes were prepared using the ammonium sulfate transmembrane gradient method. The liposomes were LUVs and were US-sensitive, exhibiting similar behavior to calcein-encapsulating liposomes. The calcein uptake by an ER + cell line (MCF-7) was compared with the uptake by an ER-cell line (MDA-MB-231). The MCF-7 uptake was significantly higher than the MDA-MB-231 uptake, which proved the targeting potential of estrone-conjugated liposomes. The exposure to low-frequency ultrasound (LFUS) revealed a statistically significant uptake of calcein compared to uptake without ultrasound. The described drug delivery (DD) system, comprising a new echogenic liposomal formulation, promises a non-immunogenic and site-specific biomedical approach to ER-positive breast cancer therapy.

show abstract

“…Endogenous stimuli in the cancerous microenvironment that can activate liposomal drug release include decreased extracellular pH, local enzymes (eg, phospholipases and reductive agents) and secreted proteases (eg, metalloproteases) . Various exogeneous stimuli have also been explored for their ability to trigger drug release from liposomes, including heat, light and ultrasound . It was this principle that was studied in the works by Hauck et al and Zimmermann et al, who investigated temperature sensitive liposomes containing DOX for spontaneous solid malignant tumours in dogs and cats .…”

Section: Challenges For Liposomal Cancer Therapy In Generalmentioning

confidence: 99%

Liposome‐encapsulated chemotherapy: Current evidence for its use in companion animals

Børresen

Hansen

Kjær

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

Cytotoxic drugs encapsulated into liposomes were originally designed to increase the anticancer response, while minimizing off-target adverse effects. The first liposomal chemotherapeutic drug was approved for use in humans more than 20 years ago, and the first publication regarding its use in a canine cancer patient was published shortly thereafter. Regardless, no general application for liposomal cytotoxic drugs has been established in veterinary oncology till now.Due to the popularity of canines as experimental models for pharmacokinetic analyses and toxicity studies, multiple publications exist describing various liposomal drugs in healthy dogs. Also, some evidence for its use in veterinary cancer patients exists, especially in canine lymphoma, canine splenic hemangiosarcoma and feline soft tissue sarcoma, however, the results have not been overwhelming. Reasons for this may be related to inherent issues with the enhanced permeability and retention effect, the tumour phenomenon which liposomal drugs exploit. This effect seems very heterogeneously distributed in the tumour. Also, it is potentially not as ubiquitously occurring as once thought, and it may prove important to select patients for liposomal therapy on an individual, non-histology-oriented, basis. Concurrently, new developments with active-release modified liposomes in experimental models and humans will likely be relevant for veterinary patients as well, and holds the potential to improve the therapeutic response. It, however, does not resolve the other challenges that liposomal chemotherapy faces, and more work still needs to be done to determine which veterinary patients may benefit the most from liposomal chemotherapy. K E Y W O R D Schemotherapy, liposomes, nanomedicine, oncology, small animal

show abstract

Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound

Cited by 47 publications

References 227 publications

Combination Strategies for Targeted Delivery of Nanoparticles for Cancer Therapy

Combination Strategies for Targeted Delivery of Nanoparticles for Cancer Therapy

Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy

Liposome‐encapsulated chemotherapy: Current evidence for its use in companion animals

Contact Info

Product

Resources

About